NASDAQ:BMRN BioMarin Pharmaceutical (BMRN) Stock Price, News & Analysis $61.79 -0.92 (-1.46%) As of 01:09 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About BioMarin Pharmaceutical Stock (NASDAQ:BMRN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BMRN alerts:Sign Up Key Stats Today's Range$60.92▼$65.4050-Day Range$55.89▼$72.8352-Week Range$52.93▼$94.85Volume849,405 shsAverage Volume1.85 million shsMarket Capitalization$11.79 billionP/E Ratio28.10Dividend YieldN/APrice Target$93.14Consensus RatingModerate Buy Company OverviewBioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.Read More… BioMarin Pharmaceutical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks99th Percentile Overall ScoreBMRN MarketRank™: BioMarin Pharmaceutical scored higher than 99% of companies evaluated by MarketBeat, and ranked 16th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingBioMarin Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on 16 buy ratings, 7 hold ratings, and no sell ratings.Amount of Analyst CoverageBioMarin Pharmaceutical has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about BioMarin Pharmaceutical's stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth38.41% Earnings GrowthEarnings for BioMarin Pharmaceutical are expected to grow by 38.41% in the coming year, from $3.15 to $4.36 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioMarin Pharmaceutical is 27.91, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 21.93.Price to Earnings Ratio vs. SectorThe P/E ratio of BioMarin Pharmaceutical is 27.91, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 22.71.Price to Earnings Growth RatioBioMarin Pharmaceutical has a PEG Ratio of 0.61. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioBioMarin Pharmaceutical has a P/B Ratio of 2.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.72% of the float of BioMarin Pharmaceutical has been sold short.Short Interest Ratio / Days to CoverBioMarin Pharmaceutical has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioMarin Pharmaceutical has recently increased by 8.32%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBioMarin Pharmaceutical does not currently pay a dividend.Dividend GrowthBioMarin Pharmaceutical does not have a long track record of dividend growth. Sustainability and ESG3.3 / 5Environmental Score-2.93 Percentage of Shares Shorted2.72% of the float of BioMarin Pharmaceutical has been sold short.Short Interest Ratio / Days to CoverBioMarin Pharmaceutical has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioMarin Pharmaceutical has recently increased by 8.32%, indicating that investor sentiment is decreasing significantly. News and Social Media3.5 / 5News Sentiment1.28 News SentimentBioMarin Pharmaceutical has a news sentiment score of 1.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.83 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 22 news articles for BioMarin Pharmaceutical this week, compared to 11 articles on an average week.Search InterestOnly 8 people have searched for BMRN on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.MarketBeat Follows10 people have added BioMarin Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is an increase of 11% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, BioMarin Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $184,521.00 in company stock.Percentage Held by InsidersOnly 0.85% of the stock of BioMarin Pharmaceutical is held by insiders.Percentage Held by Institutions98.71% of the stock of BioMarin Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BioMarin Pharmaceutical's insider trading history. Receive BMRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioMarin Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address BMRN Stock News HeadlinesBioMarin Pharmaceutical (NASDAQ:BMRN) Beats Q1 Sales TargetsMay 2 at 10:51 AM | msn.comQ1 2025 BioMarin Pharmaceutical Inc Earnings Call TranscriptMay 2 at 1:04 AM | gurufocus.comThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang said, "The ChatGPT moment for robotics is right around the corner." In fact, I believe these robots could impact 65 million Americans lives — this year. And one stock — currently priced around $7 — could be the biggest winner.May 2, 2025 | Weiss Ratings (Ad)BioMarin Pharmaceutical Inc. (BMRN) Q1 2025 Earnings Call TranscriptMay 1 at 8:02 PM | seekingalpha.comBioMarin Pharmaceutical Inc. 2025 Q1 - Results - Earnings Call PresentationMay 1 at 4:30 PM | seekingalpha.comBioMarin Reports First Quarter 2025 Results and Reaffirms Full-year GuidanceMay 1 at 4:17 PM | prnewswire.comWhat To Expect From BioMarin Pharmaceutical’s (BMRN) Q1 EarningsApril 30 at 5:24 AM | finance.yahoo.comBioMarin Pharmaceutical Inc. (BMRN): Among Billionaire Andreas Halvorsen’s Stock Picks With Huge Upside PotentialApril 29 at 12:50 PM | insidermonkey.comSee More Headlines BMRN Stock Analysis - Frequently Asked Questions How have BMRN shares performed this year? BioMarin Pharmaceutical's stock was trading at $65.73 at the beginning of 2025. Since then, BMRN shares have decreased by 6.5% and is now trading at $61.4810. View the best growth stocks for 2025 here. How were BioMarin Pharmaceutical's earnings last quarter? BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) issued its quarterly earnings data on Wednesday, February, 19th. The biotechnology company reported $0.72 earnings per share for the quarter, topping analysts' consensus estimates of $0.54 by $0.18. The biotechnology company earned $747.31 million during the quarter, compared to the consensus estimate of $711.05 million. BioMarin Pharmaceutical had a net margin of 14.96% and a trailing twelve-month return on equity of 9.91%. Read the conference call transcript. Who are BioMarin Pharmaceutical's major shareholders? Top institutional shareholders of BioMarin Pharmaceutical include Assenagon Asset Management S.A. (0.42%), Fort Washington Investment Advisors Inc. OH (0.37%), Rhumbline Advisers (0.29%) and Sumitomo Mitsui Trust Group Inc. (0.24%). Insiders that own company stock include Jean Jacques Bienaime, Henry J Fuchs, Richard A Meier, Jeffrey Robert Ajer, Brian Mueller, Charles Greg Guyer, George Eric Davis, V Bryan Lawlis, Erin Burkhart and Mark J Alles. View institutional ownership trends. How do I buy shares of BioMarin Pharmaceutical? Shares of BMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of BioMarin Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioMarin Pharmaceutical investors own include Puma Biotechnology (PBYI), Incyte (INCY), NVIDIA (NVDA), Meta Platforms (META), First Solar (FSLR), (MDVN) (MDVN) and Broadcom (AVGO). Company Calendar Last Earnings2/19/2025Today5/02/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:BMRN CIK1048477 Webwww.bmrn.com Phone(415) 506-6700Fax415-382-7889Employees3,080Year Founded1997Price Target and Rating Average Stock Price Target$93.14 High Stock Price Target$126.00 Low Stock Price Target$65.00 Potential Upside/Downside+48.5%Consensus RatingModerate Buy Rating Score (0-4)2.70 Research Coverage23 Analysts Profitability EPS (Most Recent Fiscal Year)$2.20 Trailing P/E Ratio28.50 Forward P/E Ratio19.91 P/E Growth0.61Net Income$167.65 million Net Margins14.96% Pretax Margin18.98% Return on Equity9.91% Return on Assets7.65% Debt Debt-to-Equity Ratio0.11 Current Ratio5.33 Quick Ratio2.62 Sales & Book Value Annual Sales$2.85 billion Price / Sales4.19 Cash Flow$2.96 per share Price / Cash Flow21.17 Book Value$29.69 per share Price / Book2.11Miscellaneous Outstanding Shares190,804,000Free Float187,057,000Market Cap$11.97 billion OptionableOptionable Beta0.30 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free Report This page (NASDAQ:BMRN) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeWhile everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioMarin Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioMarin Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.